drugset / Trial / NCT00986232

ProQuad Dose Selection Study (V221-011)(COMPLETED)

NCT00986232

Phase 2 Completed 1551 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindPrevention

Summary

A Study comparing three different doses of ProQuad to concomitant administration of M-M-R II and PUVV (Process Upgrade Varicella Vaccine) vaccines.

Timeline

Start
1999-04
Primary completion
2000-04
Completion
2000-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator M-M-R II Vaccine 0.5 ml Subcutaneous
Subject Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live Vaccine 0.5 ml Subcutaneous
Comparator Process Upgrade Varicella Vaccine Vaccine 0.5 ml Subcutaneous